Chest:特发性肺纤维化患者瓜氨酸蛋白IgA抗体升高

2019-12-29 xing.T MedSci原创

由此可见,IgA-ACPA在IPF患者中升高,并且与肺部淋巴样聚集物相关,支持IgA-ACPA可能在部分IPF患者的肺疾病发病机理中发挥作用。需要进一步的研究来明确ACPA阳性IPF患者的这一亚群是否与没有抗体的IPF患者不同。

特发性肺纤维化(IPF)的病因尚不清楚。近日,呼吸领域权威杂志chest上发表了一篇研究文章,由于它与类风湿性关节炎(RA)中出现的纤维化间质性肺疾病具有共同的遗传、组织病理学和影像学特征,因此,研究人员试图探究IPF中与RA相关的自身抗体。

研究人员纳入了来自国家犹太人健康和百翰妇女医院两个独立队列中的IPF受试者(N=181)、一般人群对照者(N=160)和疾病对照者(N=8640,为RA-UIP,超敏性肺炎为46名)。受试者检查了血清RA相关抗体,包括针对瓜氨酸化蛋白抗原(ACPA)的免疫球蛋白G(IgG)和IgA。研究人员检查了11名IPF受试者肺组织中是否存在异位淋巴样聚集物。

在两个独立的IPF队列中发现ACPA阳性的患病率增加。特别是,与一般人群对照者相比,在这两个IPF队列中IgA-ACPA阳性率增加(21.3%和24.8% vs. 5.6%,p<0.01)。IPF受试者为IgA-ACPA阳性几率更高,相比于IgG-ACPA(23.2% vs. 8.3%,p<0.01),而RA受试者为IgG-ACPA阳性的几率更高,相比于IgA-ACPA(72.5% vs. 52.5%,p=0.04)。在IPF中,IgA-ACPA水平与肺组织学中异位淋巴样聚集物的数量之间存在很强的相关性(r=0.72,p=0.01)。

由此可见,IgA-ACPA在IPF患者中升高,并且与肺部淋巴样聚集物相关,支持IgA-ACPA可能在部分IPF患者的肺疾病发病机理中发挥作用。需要进一步的研究来明确ACPA阳性IPF患者的这一亚群是否与没有抗体的IPF患者不同。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2071415, encodeId=57b020e14150a, content=<a href='/topic/show?id=43d894802e' target=_blank style='color:#2F92EE;'>#IgA抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9480, encryptionId=43d894802e, topicName=IgA抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Jul 09 07:34:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929604, encodeId=35441929604ac, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Nov 20 22:34:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051490, encodeId=acc32051490f0, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Sep 11 14:34:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894754, encodeId=b2d91894e5470, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Jan 09 08:34:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503937, encodeId=4069150393e9c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Dec 31 03:34:00 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2020-07-09 海豹
  2. [GetPortalCommentsPageByObjectIdResponse(id=2071415, encodeId=57b020e14150a, content=<a href='/topic/show?id=43d894802e' target=_blank style='color:#2F92EE;'>#IgA抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9480, encryptionId=43d894802e, topicName=IgA抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Jul 09 07:34:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929604, encodeId=35441929604ac, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Nov 20 22:34:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051490, encodeId=acc32051490f0, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Sep 11 14:34:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894754, encodeId=b2d91894e5470, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Jan 09 08:34:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503937, encodeId=4069150393e9c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Dec 31 03:34:00 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2020-11-20 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=2071415, encodeId=57b020e14150a, content=<a href='/topic/show?id=43d894802e' target=_blank style='color:#2F92EE;'>#IgA抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9480, encryptionId=43d894802e, topicName=IgA抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Jul 09 07:34:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929604, encodeId=35441929604ac, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Nov 20 22:34:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051490, encodeId=acc32051490f0, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Sep 11 14:34:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894754, encodeId=b2d91894e5470, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Jan 09 08:34:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503937, encodeId=4069150393e9c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Dec 31 03:34:00 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2071415, encodeId=57b020e14150a, content=<a href='/topic/show?id=43d894802e' target=_blank style='color:#2F92EE;'>#IgA抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9480, encryptionId=43d894802e, topicName=IgA抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Jul 09 07:34:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929604, encodeId=35441929604ac, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Nov 20 22:34:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051490, encodeId=acc32051490f0, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Sep 11 14:34:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894754, encodeId=b2d91894e5470, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Jan 09 08:34:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503937, encodeId=4069150393e9c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Dec 31 03:34:00 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2071415, encodeId=57b020e14150a, content=<a href='/topic/show?id=43d894802e' target=_blank style='color:#2F92EE;'>#IgA抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9480, encryptionId=43d894802e, topicName=IgA抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Jul 09 07:34:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929604, encodeId=35441929604ac, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Nov 20 22:34:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051490, encodeId=acc32051490f0, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Sep 11 14:34:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894754, encodeId=b2d91894e5470, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Jan 09 08:34:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503937, encodeId=4069150393e9c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Dec 31 03:34:00 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2019-12-31 yibei

相关资讯

PRM-151治疗特发性肺纤维化取得明显进展

Promedior是一家开发用于治疗纤维化的新疗法的临床阶段生物技术公司,近日宣布已完成与美国食品和药品管理局(FDA)的第2阶段会议,讨论PRM-151的研究。

Sci Transl Med:Caveolin-1改良肽治疗肺纤维化

特发性肺纤维化(IPF)是一种致命性的纤维化肺病,5年存活率(中位值)仅20%左右。目前,美国食品和药物管理局批准的药物疗法延缓了IPF的进展,这为开发更有效的治疗方法带来了希望。II型肺泡上皮祖细胞(AEC)的凋亡和增殖,以及活化的肌成纤维细胞或肺成纤维细胞(fLfs)的积累均可促进IPF的进展。全长的空泡蛋白-1支架结构域肽(CSP)可抑制AEC凋亡和fLf激活扩增,病可延缓博来霉素(BLM)

由于安全性问题,Biogen停止其TGF-β单抗BG00011治疗特发性肺纤维化的中期研究

根据ClinicalTrials.gov的最新消息,由于"安全问题",Biogen停止了其实验药物BG00011在特发性肺纤维化(IPF)患者中的II期研究。该试验于去年9月开始,预计将招募多达290名IPF的受试者。

特发性肺纤维化急性加重诊断和治疗中国专家共识

特发性肺纤维化(IPF)是一种病因未明的慢性进展性纤维化肺疾病,组织病理学和(或)胸部高分辨率CT(HRCT)特征为普通型问质性肺炎(uIP)。IPF患者从诊断开始中位生存期仅2~3年。部分患者在短期内可出现急性呼吸功能恶化,称之为IPF急性加重(AE—IPF),是IPF患者死亡的重要原因。由于AE-IPF患者病情危重,进展迅速,预后差,近年来对其研究和认识不断深入,国际上对AE-IPF的定义及诊

Radiology:超极化3He扩散加权MRI在评估特发性肺纤维化气道结构的价值

背景:吸入超极化3He进行MRI检查有助于评价肺功能和结构。超极化其他扩散加权(DW)MRI能够非侵入性定量评价肺腺泡结构微观结构。

Thorax:奥美拉唑治疗特发性肺纤维化的疗效

由此可见,这项针对IPF咳嗽的PPI大型随机对照试验似乎是可行且合理的,但应解决随机化的障碍,并纳入与呼吸道感染和肺功能变化相关的安全性评估指标。